Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Annovis Bio, Inc.NYSE: ANVS
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets broadly unchanged from a year ago
Other current assets stood at $7.5K at the end of Q1 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at -90.0% a year.
Context
- Other current assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.5K USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- -6.6%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.5K | +0.0% |
| FY2024 | 2024-12-31 | 7.5K | -64.0% |
| FY2023 | 2023-12-31 | 20.8K | -99.7% |
| FY2022 | 2022-12-31 | 7.54M | +76326.6% |
| FY2021 | 2021-12-31 | 9.87K | — |
Other Current Assets vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 other current assets of $7.5K is the 5th highest of the 6 companies compared; the peer median is $351K.
- Its year-over-year change of +0.0% is the highest of 6, against a peer median of -52.1%.
- Other current assets amounts to 0.0% of total assets for ANVS, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.23M | -50.8% | -16.6% | 5.0% | |
| Mar 2026 | $902.02K | -2.0% | — | 2.6% | |
| Mar 2026 | $351K | -52.1% | -36.4% | 1.8% | |
| Dec 2025 | $222K | -74.1% | -40.4% | 0.2% | |
| Mar 2026 | $7.5K | +0.0% | -90.0% | 0.0% | |
| Jun 2026 | $0 | -100.0% | +51.7% | 0.0% | |
| Peer median (excluding ANVS) | $351K | -52.1% | -26.5% | 1.8% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.